145 related articles for article (PubMed ID: 36173049)
1. Anti-nucleolin Aptamer as a Boom in Rehabilitation of Breast Cancer.
Janani SK; Dhanabal SP; Sureshkumar R; Nikitha Upadhyayula SS
Curr Pharm Des; 2022; 28(38):3114-3126. PubMed ID: 36173049
[TBL] [Abstract][Full Text] [Related]
2. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
Reyes-Reyes EM; Teng Y; Bates PJ
Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
Reyes-Reyes EM; Šalipur FR; Shams M; Forsthoefel MK; Bates PJ
Mol Oncol; 2015 Aug; 9(7):1392-405. PubMed ID: 25911416
[TBL] [Abstract][Full Text] [Related]
4. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-Aptamer Chimera for Targeted Delivery and ATP-Responsive Release of Doxorubicin into Cancer Cells.
Esawi E; Alshaer W; Mahmoud IS; Alqudah DA; Azab B; Awidi A
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884745
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.
Holmboe S; Hansen PL; Thisgaard H; Block I; Müller C; Langkjær N; Høilund-Carlsen PF; Olsen BB; Mollenhauer J
PLoS One; 2017; 12(5):e0178286. PubMed ID: 28542563
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic applications of AS1411 aptamer, an update review.
Yazdian-Robati R; Bayat P; Oroojalian F; Zargari M; Ramezani M; Taghdisi SM; Abnous K
Int J Biol Macromol; 2020 Jul; 155():1420-1431. PubMed ID: 31734366
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
Noaparast Z; Hosseinimehr SJ; Piramoon M; Abedi SM
J Drug Target; 2015; 23(6):497-505. PubMed ID: 25673264
[TBL] [Abstract][Full Text] [Related]
9. Anti-nucleolin aptamer AS1411: an advancing therapeutic.
Van den Avont A; Sharma-Walia N
Front Mol Biosci; 2023; 10():1217769. PubMed ID: 37808518
[TBL] [Abstract][Full Text] [Related]
10. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ
Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443
[TBL] [Abstract][Full Text] [Related]
11. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
12. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579
[TBL] [Abstract][Full Text] [Related]
13. Direct investigations of interactions between nucleolins and aptamers on pancreatic cancer and normal cells by atomic force microscopy.
Li X; Chen L; Kong S; Zhong H; Jiang F; Zhao W
Ultramicroscopy; 2024 Sep; 263():113986. PubMed ID: 38762964
[TBL] [Abstract][Full Text] [Related]
14. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
[TBL] [Abstract][Full Text] [Related]
15. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411.
Sharma VR; Thomas SD; Miller DM; Rezzoug F
Cancer Invest; 2018; 36(9-10):475-491. PubMed ID: 30396283
[TBL] [Abstract][Full Text] [Related]
16. AS1411 Aptamer-Decorated Biodegradable Polyethylene Glycol-Poly(lactic-co-glycolic acid) Nanopolymersomes for the Targeted Delivery of Gemcitabine to Non-Small Cell Lung Cancer In Vitro.
Alibolandi M; Ramezani M; Abnous K; Hadizadeh F
J Pharm Sci; 2016 May; 105(5):1741-1750. PubMed ID: 27039356
[TBL] [Abstract][Full Text] [Related]
17. An exploration of aptamer internalization mechanisms and their applications in drug delivery.
Wan LY; Yuan WF; Ai WB; Ai YW; Wang JJ; Chu LY; Zhang YQ; Wu JF
Expert Opin Drug Deliv; 2019 Mar; 16(3):207-218. PubMed ID: 30691313
[TBL] [Abstract][Full Text] [Related]
18. Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells
Xing H; Tang L; Yang X; Hwang K; Wang W; Yin Q; Wong NY; Dobrucki LW; Yasui N; Katzenellenbogen JA; Helferich WG; Cheng J; Lu Y
J Mater Chem B; 2013 Oct; 1(39):5288-5297. PubMed ID: 24159374
[TBL] [Abstract][Full Text] [Related]
19. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M
Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548
[TBL] [Abstract][Full Text] [Related]
20. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.
Liang X; Wang Y; Shi H; Dong M; Han H; Li Q
Int J Nanomedicine; 2021; 16():2569-2584. PubMed ID: 33833512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
